Arvinas Inc (ARVN)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | John G. Houston |
| Employees: | 420 |
| Web site: | arvinas.com |
|
395 WINCHESTER AVE, 5 SCIENCE PARK, NEW HAVEN, CT, 06511
203-535-1456
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
Please log in first to see chart